Aims Little is known about the clinical relevance of interleukin (IL)-6 in patients with acute ST-
elevation myocardial infarction (STEMI). This study examined the possible associations of …

Background We recently showed that interleukin (IL)-6 inhibition by tocilizumab improves
myocardial salvage in ST-elevation myocardial infarction (STEMI). However, the …

Abstract Aims Interleukin-6 receptor (IL-6R) signalling has been suggested to play a causal
role in the development and outcome of coronary heart disease (CHD). The aim of this study …

Two pilot studies of interleukin-1 (IL-1) blockade in ST-segment elevation myocardial
infarction (STEMI) showed blunted acute inflammatory response and overall favorable …

ST-segment elevation myocardial infarction (STEMI) is still a leading cause of mortality and
morbidity worldwide. The widespread use of reperfusion, mainly primary percutaneous …

Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been
shown to reduce the inflammatory response as well as prevent heart failure (HF) events in …

Background Inhibition of the interleukin-1β (IL-1β) innate immunity pathway is associated
with anti-inflammatory effects and a reduced risk of recurrent cardiovascular events in stable …

Background: Little is known about the role of interleukin (IL)-8 in patients with acute ST-
segment elevation myocardial infarction (STEMI). Objectives: The aims of this study were to …

Abstract Background and Aim ST-Segment Elevation Myocardial Infarction (STEMI) is a life-
threatening condition caused by sudden blockage of infarct-related artery and is one of the …

Background Inhibition of the interleukin (IL)-1β innate immunity pathway is associated with
anti-inflammatory effects and a reduced risk of recurrent cardiovascular events in stable …